NEWSROOM | Galderma

Galderma opens up new chapter for Sculptra® with MDR certification and new expanded indication for body

Galderma secures ‘BBB’ credit rating with positive outlook from S&P Global Ratings

ASDS 2025: Compelling new data on Restylane, Sculptra and Relfydess highlight Galderma’s innovative Injectable Aesthetics portfolio and pipeline

Galderma completes successful placement of CHF 175 million bond

ASDS 2025: Galderma’s scientific presentations

Galderma receives U.S. FDA approval for Restylane® Lyft™ for the enhancement of the chin profile

Two patients, one condition: the overlooked impact of atopic dermatitis on families

Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance

AMWC Dubai 2025: Galderma’s Scientific Presentations

AMWC Dubai: Galderma demonstrates Injectable Aesthetics leadership through updates on its scientific innovations and community education

Galderma launches transformative skincare segment with Cetaphil’s new Skin Activator Hydrating & Firming Line, in partnership with actor and filmmaker Mariska Hargitay

Galderma’s groundbreaking real-world study reveals the biological toll of modern living and urban environments on sensitive skin

EADV 2025: Galderma reinforces leadership in dermatology with latest advances in sensitive skin and itch